Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624837 | 0.85 | OPRM1 (0.51) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL14263076 | 0.81 | OPRD1 (0.37) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13507183 | 0.78 | OPRM1 (0.52) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL12449823 | 0.76 | OPRD1 (0.56) | OPRM1OPRD1OPRK1CYP2D6CYP1A2 | |
| SCHEMBL20170852 | 0.75 | OPRM1 (0.53) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL18104558 | 0.74 | OPRM1 (0.44) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL13507285 | 0.72 | OPRM1 (0.50) | OPRM1OPRD1OPRK1CYP1A2PKM | |
| SCHEMBL7987517 | 0.70 | OPRM1 (0.52) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL16311903 | 0.70 | OPRM1 (0.45) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL16311868 | 0.70 | OPRM1 (0.43) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064743-A1 | Dry powder compound formulations and uses thereof | WYETH (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064743-A1 | Dry powder compound formulations and uses thereof | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.